Clinical trial

Protocol for Herceptin as Adjuvant Therapy With Reduced Exposure to Chemotherapy (PHARE-C)

NCT05388500

StatusNOT_YET_RECRUITING

Study typeINTERVENTIONAL

Start date2022-12-15

PhasePHASE3

Study timeline

Study start (estimated)2022-12-15Date precision: day

Registry last updated2022-05-27

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

HER2-positive Breast Cancerunresolved

Interventions

Paclitaxel + TrastuzumabDRUG

TrastuzumabDRUG · verified · RxNorm: trastuzumab

Sponsors & collaborators

Institut de cancérologie Strasbourg Europelead sponsor

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT05388500 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.